IDP was the active ingredient in a specially formulated skin cream that went head-to-head in a double blind study against a premium, US-based clinical brand of acne treatment cream (containing 2% salicylic acid plus retinal). Results were presented at the New Zealand Dermatological Society Annual Meeting in Coolum, Australia last week.
At the conclusion of the 42 day trial period involving 84 subjects, both the premium brand of acne treatment cream and the IDP-based cream showed statistically equivalent results in terms of total reduction in acne lesions. The IDP-based cream also showed a major improvement of over 52% in reduction of redness and inflammation.
As part of the clinical assessment, the IDP-based cream also passed specific testing for use on subjects with sensitive skin, making it the superior performer of the two products and ideal for users with hyper-reactive and sensitive skin.
Results at a glance:
Study compared IDP®-based cream with premium, US-based clinical brand of acne treatment cream
Statistically equivalent results in terms of total reduction in acne lesions
IDP-based cream showed over 52% improvement in reduction of redness and inflammation
IDP-based cream passed specific testing for use on subjects with sensitive skin
Founder and Managing Director of Quantec Ltd, Dr Rod Claycomb explains that, "IDP® is a unique and naturally derived complex of bio-proteins. These bio-proteins have unique properties, which make them very powerful against certain types of disease-causing bacteria which leave the natural and beneficial bacteria of the skin largely unaffected.
"By leaving these natural and beneficial bacteria active on the skin, IDP® creates a perfect scenario for treatment and management of acne. In addition, the IDP® bio-proteins signal directly to inflamed tissues and cells to quell the inflammatory response. IDP® contains what we refer to as 'Triple-A' activity - antibacterial, anti-inflammatory and antioxidant."
Dr Claycomb said Quantec was founded on the value that all its products are proven through science and so it was important to the company to unveil IDP and its efficacy as an acne treatment to dermatologists first prior to developing and launching a commercial acne product.
"Quantec is a company committed to developing high-value bioactives from natural products, which are backed with solid science. It has taken our research and development team 7 years to create IDP® and now prove its efficacy as an acne treatment. Therefore, it was important to us to detail the results of our clinical trial and gain the backing of industry-leading dermatologists prior to a commercial product launch."
- Galderma Announces Approval For Differin(R) Gel 0.1% In Japan
- Negative Perceptions Of Teenagers With Acne
- IDP Education Announces First Two Clients In United Kingdom Expansion
- Women More Likely Than Men To Be Affected By Acne As Adults
- Solta Medical Introduces Liposonix® At AMWC In Monaco And Announces Its Portfolio Of Aesthetic Energy Devices Reaches Industry Milestone With More Than 2 Million Procedures Completed Globally